Claim: Sanofi's Lantus insulin favored over rival: study.
Verdict: SUPPORTS

Retrieved passages:
title: Insulin analog
text: to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir). Sanofi-Aventis developed glargine as a longer-lasting insulin analogue, and markets it under the trade name Lantus. It was created by modifying three amino acids. Two positively charged arginine molecules were added to the C-terminus of the B-chain, and they shift the isoelectric point from 5.4 to 6.7, making glargine more soluble at a slightly acidic pH and less soluble at a physiological pH. Replacing the acid-sensitive asparagine at position 21 in the A-chain by glycine is needed to avoid deamination and dimerization

title: Insulin glargine
text: to over 100 countries and more than 3,5 million patients worldwide. This makes Lantus Germany's largest and most important export pharmaceutical product. Sanofi-Aventis increased its turn-over with Lantus around 28% to 2,45 million €, therefrom 130 Million € in Germany, where approx. 1.8 million people with diabetes use the product. In 2007 Lantus was the 15th highest selling pharmaceutical product in Germany. The investment in the production of Lantus and insulin-pen-manufacturing in Frankfurt-Höchst cost 700 Million €. In 2008 a new manufacturing plant was established for further insulin-pen manufacturing with an investment of 150 Million €. At Sanofi-Aventis the production

title: Intensive insulin therapy
text: ultralente, and beef ultralente in particular was considered for decades to be the gold standard of basal insulin. Long-acting insulin analogs such as insulin glargine (brand name "Lantus", made by Sanofi-Aventis) and insulin detemir (brand name "Levemir", made by Novo Nordisk) are also used, with insulin glargine used more than insulin detemir. Rapid-acting insulin analogs such as lispro (brand name "Humalog", made by Eli Lilly and Company) and aspart (brand name "Novolog"/"Novorapid", made by Novo Nordisk and "Apidra" made by Sanofi Aventis) are preferred by many clinicians over older regular insulin for meal coverage and high correction. Many people on

title: Insulin glargine/lixisenatide
text: controversy around the risks of Avandia) Sanofi decided to withdraw the NDA and wait for the results of a Phase III study that was scheduled to be completed in 2015. Sanofi resubmitted the application which the FDA accepted in September 2015, by which time Sanofi had lost the lead in the field of anti-diabetic drugs to Novo Nordisk. Lixisenatide received FDA approval on July 28, 2016. In 2010, Sanofi extended a license agreement it had with Zealand for lixisenatide to allow Sanofi to combine it with insulin glargine, which was Sanofi's best selling drug at the time, with sales of

title: Aventis Pharma
text: Aventis Pharma Sanofi India Limited, headquartered in Mumbai, is a part of Sanofi group. Sanofi SA and its wholly owned subsidiary Hoechst AG, are the major shareholders of Sanofi India Limited. Its manufacturing portfolio contains medicines for several therapeutic areas including cardiovascular, thrombotic, metabolic disorders, oncology, disorders of the central nervous system, internal medicine. Its primary business is medicines in the dosage forms of liquid injectables, tablets, capsules, ointments, drops and syrup. In July 2003, company launched Lantus, the world's first and only once a day insulin. Sanofi India Limited was incorporated in May 1956 under the name Hoechst Fedco

title: Insulin glargine/lixisenatide
text: around €3 billion in 2009. Sanofi planned to start the Phase III trial that year. Sanofi submitted the new drug application in December 2015 for the combination and spent a $245M priority voucher to gain a faster review, to try to outrace Novo Nordisk’s Xultophy, a similar combination drug of Novo's insulin Tresiba and Novo's GLP-1 agonist Victoza. Sanofi's application was considered by the same Endocrinologic and Metabolic Drugs Advisory FDA Committee that was considering lixisenatide as a single agent. In May 2016 by a vote of 12-2, with several members of the committee expressing reservations about Sanofi's plans to

title: Lixisenatide
text: start the Phase III trial that year. Sanofi submitted the NDA in December 2015 for the combination, called LixiLan and it was considered by the same Endocrinologic and Metabolic Drugs Advisory FDA Committee that was considering lixisenatide as a single agent. In May 2016 by a vote of 12-2, with several members of the committee expressing reservations about Sanofi's plans to offer two pens with different ratios of insulin glargine and lixisenatide - one for people who had never taken insulin before and one for people who had; there was also concern about how to handle dosing when switching people

title: Insulin analog
text: Cochrane's findings. In 2007, Germany's Institute for Quality and Cost Effectiveness in the Health Care Sector (IQWiG) reached a similar conclusion based on absence of conclusive double-blind comparative studies. In its report, IQWiG concluded that there is currently "no evidence" available of the superiority of rapid-acting insulin analogs over synthetic human insulins in the treatment of adult patients with type 1 diabetes. Many of the studies reviewed by IQWiG were either too small to be considered statistically reliable and, perhaps most significantly, none of the studies included in their widespread review were blinded, the gold-standard methodology for conducting clinical research.

title: Sanofi
text: a strong role, desiring what it called a "local solution", by putting heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis and for Aventis to accept the offer and by rejecting Aventis' poison pill proposal. One of the largest risks in the deal for both sides, was the fate of the patents protecting Clopidogrel (Plavix) which was one of the top-selling drugs in the world at the time and the major source of Sanofi's revenue. In 2006, Iraqis infected with HIV sued Sanofi and Baxter due to HIV-contaminated haemophilia blood products sold by Merieux in the 1980s. In 2006

title: Insulin analog
text: the yeast genome, and the yeast expressed the insulin analogue, which was then harvested from a bioreactor. This analogue also prevents the formation of hexamers, to create a faster acting insulin. It is approved for use in CSII pumps and Flexpen, Novopen delivery devices for subcutaneous injection. Glulisine is rapid acting insulin analog from Sanofi-Aventis, approved for use with a regular syringe, in an insulin pump. Standard syringe delivery is also an option. It is sold under the name Apidra. The FDA-approved label states that it differs from regular human insulin by its "rapid onset and shorter duration of action".

title: Sanofi
text: other agents, under the brand name ZALTRAP in 2012. Sanofi-Aventis was formed in 2004 when Sanofi-Synthélabo acquired Aventis. In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 billion for Aventis. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company's share value, and the board of Aventis went so far as to enact poison pill provisions and to invite Novartis to enter merger negotiations. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 billion in place of the previously rejected hostile bid. The French government played

title: Insulin
text: and animal insulins. The other type is long acting insulin; the first of these was Lantus (insulin glargine). These have a steady effect for an extended period from 18 to 24 hours. Likewise, another protracted insulin analogue (Levemir) is based on a fatty acid acylation approach. A myristic acid molecule is attached to this analogue, which associates the insulin molecule to the abundant serum albumin, which in turn extends the effect and reduces the risk of hypoglycemia. Both protracted analogues need to be taken only once daily, and are used for type 1 diabetics as the basal insulin. A combination

title: Vaccine bundling
text: Sanofi Pasteur Inc. with violating U.S. antitrust laws, as a result of its bundling practices. The suits challenge Sanofi's alleged “anticompetitive scheme” to maintain its monopoly in the U.S. meningitis vaccine market. These lawsuits have since been consolidated. In both cases, plaintiffs were parties to exclusionary contracts with Sanofi Pasteur to purchase vaccines. Each plaintiff wanted to purchase a different meningitis vaccine manufactured by Novartis that they thought to be superior. According to documents, if they purchased this vaccine and therefore did not use Sanofi’s pediatric vaccines exclusively, they would have to pay Sanofi 15 to 34 percent higher prices

title: Vaccine bundling
text: for all Sanofi vaccines. The lawsuits claim that, due to Sanofi’s prominence in the vaccine market, the contracts make it virtually impossible for competitors to gain any market share. Sanofi responded that there are alternatives to all of the vaccines in the bundle, and that Novartis already has 20 percent of the market share for its competing vaccine. In defending its practices, Sanofi contended the plaintiffs did not claim they were coerced by the bundling into not purchasing other vaccines, and did not have standing to sue because the bundling contracts were negotiated by physician buying groups, not the individual

title: Sanofi Pasteur
text: Sanofi Pasteur Sanofi Pasteur is the vaccines division of the multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines. Sanofi Pasteur is one of four global producers of the yellow fever vaccine. In 2004, Aventis merged with and into Sanofi. The new Sanofi-Aventis Group became the world's 3rd largest pharmaceutical company. Aventis Pasteur, the vaccine division of Sanofi-Aventis Group, changed its name to Sanofi Pasteur. In 2014, Sanofi Pasteur stopped producing its effective Fav-Afrique antivenom because competition from cheaper though less powerful competitors made it unprofitable. Doctors Without Borders said that it

title: Sanofi
text: 2013. In 2007 Sanofi-Aventis expanded on Aventis' prior relationship with Regeneron; in the new deal Sanofi-Aventis agreed to pay Regeneron $100 million each year for five years, under which Regeneron would use its monoclonal antibody discovery platform to create new biopharmaceuticals, which Sanofi-Aventis gained the exclusive right to co-develop. In 2009 the companies expanded the deal to $160 million per year and extended it through 2017. As of 2009 the collaboration had four antibodies in clinical development and had filed an IND for a fifth. Two were against undisclosed targets, one targeted the interleukin-6 receptor as a treatment for rheumatoid

title: Insulin glargine
text: of Lantus created 3000 jobs in Berlin and Frankfurt-Höchst. On June 9, 2000 the European Commission formally approved the launching of Lantus by Sanofi-Aventis Germany Ltd. in the entire European Union. The admission was prolonged on June 9, 2005. A three-fold more concentrated formulation, brand name Toujeo, was introduced after FDA approval in 2015. Patent protection for insulin glargine expired in most countries in 2015. Insulin glargine from competitor Eli Lilly became available in most countries during 2015, under the brand names Basaglar (as a follow-on in the US) and Abasaglar (as a biosimilar in the EU). Biosimilar insulin glargine

title: Inhalable insulin
text: trials to ensure that people would use it the same way as the earlier versions. After conducting further studies, Mannkind submitted a new application, and in June, 2014, the FDA approved Afrezza for both Type I and Type II adult diabetics, with a label restriction for patients having asthma, active lung cancer or COPD. In 2014 Mannkind and Sanofi agreed that Sanofi would take over manufacturing and marketing of Afrezza, but Sanofi said it was dropping the effort in January 2016 due to poor sales of $7.5 million in 2015; the companies formally terminated the agreement in November 2016. At

title: Sanofi Biogenius Canada
text: for Health Research, and the Centre for Drug Research and Development. The competition is intended to assist students in carrying out their biotechnology research ideas, with students often basing their projects on personal scientific knowledge and around individual concerns. Students receive mentorship from local scientists and researchers on how to design a research plan, carry out experimental work, collect data, and analyze their findings for presentation to the regional competition audience. Occasionally, students may gain the opportunity to publish their work, thus giving them a more complete scientific research experience. In the spring of each year, students present their research

title: Insulin glargine
text: Insulin glargine Insulin glargine, marketed under the names Lantus, among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert). Pharmacokinetically, its steady action can supplement the variable insulin secretion of non-diabetic pancreatic beta cells. Sometimes, in type 2 diabetes and in combination with a short acting sulfonylurea (drugs which stimulate the pancreas to make more insulin), it can